RT Book, Section
A1 Popma, Jeffrey J.
A2 Samady, Habib
A2 Fearon, William F.
A2 Yeung, Alan C.
A2 King III, Spencer B.
SR Print(0)
ID 1146603756
T1 Clinical Outcomes with Self-Expanding Transcatheter Aortic Valve Bioprostheses
T2 Interventional Cardiology, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071820363
LK accesscardiology.mhmedical.com/content.aspx?aid=1146603756
RD 2024/04/23
AB Since  the  introduction  of  the  18-Fr  CoreValve  self-expanding  transcatheter  aortic  valve  replacement  (TAVR),  over  70,000  implants  have  been  performed  worldwide.  The  use  of  this  self-expanding  bioprosthesis  has  provided  an  alternative  to  surgery  in  patients  who  are  suboptimal  for  conventional  surgical  aortic  valve  replacement  and  has  resulted  in  improved  survival  and  quality  of  life  for  thousands  of  patients  worldwide.  There  are  a  number  of  potential  advantages  of  a  self-expanding  bioprosthesis  over  alternative  transcatheter  designs,  including  the  progressive  self-expansion  of  the  inflow  frame  reducing  the  degree  of  paravalvular  regurgitation  (PVR)  over  time;  supra-annular  location  of  the  porcine  pericardial  valve,  which  improves  hemodynamics  and  potentially  improves  long-term  durability;  and  large  cell  diameter,  which  provides  access  to  coronary  arteries  after  implantation.